ArticleThe journal of allergy and clinical immunology. Global2026
Biologic outcomes in patients with severe asthma and clinically relevant allergy in the CHRONICLE study.
Article in The journal of allergy and clinical immunology. Global, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Several mAb biologic therapies are approved for the treatment of severe asthma. There are limited data examining biologic outcomes in patients with allergy that has been clinically confirmed to exacerbate their asthma symptoms. Objective: Our aim was to assess rates of asthma exacerbations, exacerbation-related emergency department (ED) visits, and exacerbation-related hospitalizations before and after biologic initiation among adults with severe asthma and confirmed clinically relevant allergy. Methods: CHRONICLE was an observational study of subspecialist-treated US adults with severe asthma. Annualized rates of asthma exacerbations, exacerbation-related ED visits, and exacerbation-related hospitalizations (6 months before and after initiation of biologic treatment) were compared for patients who had clinician-confirmed clinically relevant allergy and regular exposure to relevant asthma-exacerbating allergens and were enrolled between February 2018 and February 2024. Results: Overall, 214 patients with confirmed allergy and regular allergen exposure were analyzed (67% were female and 76% were White; the mean age at enrollment was 53 years). After initiation of biologics, the rates of asthma exacerbations, exacerbation-related ED visits, and exacerbation-related hospitalizations decreased by 61% (decreasing from 1.49 to 0.58 per patient year [ Conclusion: Among this cohort of US subspecialist-treated adults with severe asthma and clinically relevant allergy, biologics decreased the rates of exacerbations, exacerbation-related ED visits, and exacerbation-related hospitalizations, regardless of biologic subgroup.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.